These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 15971961)

  • 1. Some tolerance for fur--animal studies in PLoS Medicine.
    The
    PLoS Med; 2005 Jun; 2(6):e203. PubMed ID: 15971961
    [No Abstract]   [Full Text] [Related]  

  • 2. Vesicular stomatitis virus-based vaccines against Lassa and Ebola viruses.
    Marzi A; Feldmann F; Geisbert TW; Feldmann H; Safronetz D
    Emerg Infect Dis; 2015 Feb; 21(2):305-7. PubMed ID: 25625358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a new vaccine for the prevention of Lassa fever.
    Geisbert TW; Jones S; Fritz EA; Shurtleff AC; Geisbert JB; Liebscher R; Grolla A; Ströher U; Fernando L; Daddario KM; Guttieri MC; Mothé BR; Larsen T; Hensley LE; Jahrling PB; Feldmann H
    PLoS Med; 2005 Jun; 2(6):e183. PubMed ID: 15971954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective vaccine for lassa fever.
    Fisher-Hoch SP; Hutwagner L; Brown B; McCormick JB
    J Virol; 2000 Aug; 74(15):6777-83. PubMed ID: 10888616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccine platforms to control Lassa fever.
    Lukashevich IS; Pushko P
    Expert Rev Vaccines; 2016 Sep; 15(9):1135-50. PubMed ID: 27136941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lassa fever: epidemiology, therapy and vaccine development.
    McCormick JB
    Kansenshogaku Zasshi; 1988 Mar; 62 Suppl():353-66. PubMed ID: 3138361
    [No Abstract]   [Full Text] [Related]  

  • 7. Vaccinia recombinant expressing Lassa-virus internal nucleocapsid protein protects guineapigs against Lassa fever.
    Clegg JC; Lloyd G
    Lancet; 1987 Jul; 2(8552):186-8. PubMed ID: 2885642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [An evaluation of the possibility of obtaining an inactivated vaccine against Lassa fever].
    Krasnianskiĭ VP; Potryvaeva NV; Borisevich IV; Gradoboev VN; Pashanina TP; Pshenichnov VA
    Zh Mikrobiol Epidemiol Immunobiol; 1994; (6):74-5. PubMed ID: 7879553
    [No Abstract]   [Full Text] [Related]  

  • 9. [Development and study of properties of immunoglobulins against Lassa fever].
    Krasnianskiĭ VP; Gradoboev VN; Borisevich IV; Potryvaeva NV; Lebedinskaia EV; Chernikova NK; Timan'kova GD
    Vopr Virusol; 1997; 42(4):168-71. PubMed ID: 9304297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Use of guinea pigs for assessing the efficacy of vaccines against Lassa fever].
    Firsova IV; Shatokhina IV; Borisevich IV; Evseev AA; Maksimov VA; Pantiukhov VB; Khmelev AL
    Vopr Virusol; 2003; 48(6):43-5. PubMed ID: 14708232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A trial to produce an inactivated Lassa fever vaccine].
    Krasnianskiĭ VP; Potryvaeva NV; Borisevich IV; Gradoboev VN; Pashanina TP; Pshenichnov VA
    Vopr Virusol; 1993; 38(6):276-9. PubMed ID: 8303891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Experimental Lassa infection in monkeys and its treatment with ribamidil].
    Fidarov FM; Sabynin VM; Petkevich AS; Surikova LE; Vladyko AS; Lukashevich IS
    Vopr Virusol; 1990; 35(6):504-6. PubMed ID: 2082557
    [No Abstract]   [Full Text] [Related]  

  • 13. A review of Lassa fever vaccine candidates.
    Salami K; Gouglas D; Schmaljohn C; Saville M; Tornieporth N
    Curr Opin Virol; 2019 Aug; 37():105-111. PubMed ID: 31472333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Possible approaches to a vaccine against Lassa fever.
    Clegg JC
    Trans R Soc Trop Med Hyg; 1984; 78(3):307-10. PubMed ID: 6464128
    [No Abstract]   [Full Text] [Related]  

  • 15. Pathobiology of Lassa fever.
    Buckley SM; Casals J
    Int Rev Exp Pathol; 1978; 18():97-136. PubMed ID: 350792
    [No Abstract]   [Full Text] [Related]  

  • 16. Imported Lassa fever in Germany: surveillance and management of contact persons.
    Haas WH; Breuer T; Pfaff G; Schmitz H; Köhler P; Asper M; Emmerich P; Drosten C; Gölnitz U; Fleischer K; Günther S
    Clin Infect Dis; 2003 May; 36(10):1254-8. PubMed ID: 12746770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection From Lethal Lassa Disease Can Be Achieved Both Before and After Virus Exposure by Administration of Single-Cycle Replicating Lassa Virus Replicon Particles.
    Kainulainen MH; Spengler JR; Welch SR; Coleman-McCray JD; Harmon JR; Scholte FEM; Goldsmith CS; Nichol ST; Albariño CG; Spiropoulou CF
    J Infect Dis; 2019 Sep; 220(8):1281-1289. PubMed ID: 31152662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A single shot vaccine against Lassa fever].
    Baize S
    Med Sci (Paris); 2020 Oct; 36(10):844-847. PubMed ID: 33026323
    [No Abstract]   [Full Text] [Related]  

  • 19. Molecular and cell biology of the prototypic arenavirus LCMV: implications for understanding and combating hemorrhagic fever arenaviruses.
    de la Torre JC
    Ann N Y Acad Sci; 2009 Sep; 1171 Suppl 1():E57-64. PubMed ID: 19751403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever.
    Mire CE; Cross RW; Geisbert JB; Borisevich V; Agans KN; Deer DJ; Heinrich ML; Rowland MM; Goba A; Momoh M; Boisen ML; Grant DS; Fullah M; Khan SH; Fenton KA; Robinson JE; Branco LM; Garry RF; Geisbert TW
    Nat Med; 2017 Oct; 23(10):1146-1149. PubMed ID: 28869611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.